Duaa H. Al-Rawi, MD, PhD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Gynecologic cancers and conditions
- Ovarian cancers and conditions
- Uterine cancers and conditions
Get to Know Me
I am a gynecologic medical oncologist who specializes in the diagnosis and treatment of ovarian cancer, endometrial cancer, and cervical cancer.
I became interested in the field of oncology while I was pursuing my PhD at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. During my doctoral training, I studied the biochemical functions of the genes that lead to higher risk of breast and ovarian cancer, including the BRCA1 gene. My interactions with physician-scientists and their patients inspired me to care for people diagnosed with cancer.
This led me to transition to medical school at Stanford University where I pursued an internal medicine residency. I enjoy caring for patients and I connected most strongly with the women who came to me for care, which led me to focus on gynecologic medical oncology. I pursued my medical fellowship at Memorial Sloan Kettering Cancer Center (MSK), one of the few centers where medical oncologists treat people with gynecologic cancers. I was excited by the opportunity to train at MSK and feel deeply privileged to care for people with gynecologic cancers.
A cancer diagnosis can emotionally and physically challenging and I aim to create a warm environment for my patients. Beyond providing excellent clinical care, I welcome patients from diverse backgrounds and aim to honor their values. This extends from respecting cultural and religious values, using preferred pronouns, and being open during challenging discussions. I aim to support both my team and my patients to create a culture of mutual respect.
My research is focused on modeling and detecting early invasive ovarian cancer by studying serous tubal intraepithelial carcinoma (STIC) lesions, which are benign lesions inside the fallopian tube. People with STIC lesions may be at higher risk of developing cancer and I use single cell sequencing and spatial transcriptomics to research how these lesions can lead to ovarian cancer.
I am passionate about improving treatment and detection of ovarian cancer through a better understanding of how ovarian cancer originates or develops. It is critical that we provide monitoring for people who are found to have STIC lesions while we work to identify their levels of risk for cancer and determine the best surveillance and treatment guidelines for them.
Outside of clinical care and research, I enjoy spending time with my family, going to farmers markets, traveling, exploring New York City, and cooking.
I'm a gynecologic medical oncologist, which is a cancer doctor who specializes in gynecologic (GY-neh-kuh-LAH-jik) cancers. This includes cervical, fallopian tube, ovarian, uterine (endometrial), vaginal, and vulvar cancers.
- Instructor
Conditions I Treat
- Gynecologic cancers and conditions
- Ovarian cancers and conditions
- Uterine cancers and conditions
- Cervical cancers and conditions
Residencies
- Internal Medicine, Stanford University Medical Center
Fellowships
- Medical Oncology, Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine, Medical Oncology
Awards and Honors
- Ovarian Cancer Research Alliance, Mentored Investigator Grant (2023-24)
- Conquer Cancer Foundation, Young Investigator Award (2024)
- Mary Kay Ash Foundation Pilot Research Grant (2022-24)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
State Government
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
1. Agustinus AS, Al-Rawi D, Dameracharla B, Raviram R, Jones BSCL, Stransky S, Scipioni L, Luebeck J, Di Bona M, Norkunaite D, Myers RM, Duran M, Choi S, Weigelt B, Yomtoubian S, McPherson A, Toufektchan E, Keuper K, Mischel PS, Mittal V, Shah SP, Maciejowski J, Storchova Z, Gratton E, Ly P, Landau D, Bakhoum MF, Koche RP, Sidoli S, Bafna V, David Y, Bakhoum SF. Epigenetic dysregulation from chromosomal transit in micronuclei. Nature. 2023 Jul;619(7968):176-183. PubMed Central PMCID: PMC10322720.
2. Al-Rawi DH, Rusk N, Friedman CF. The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer. Clin Cancer Res. 2023 May 1;29(9):1645-1647. PubMed Central PMCID: PMC10159911.
3. Al-Rawi DH, Bakhoum SF. Chromosomal instability as a source of genomic plasticity. Curr Opin Genet Dev. 2022 Jun;74:101913. PubMed Central PMCID: PMC9156567.
4. Navitski A, Al-Rawi DH, Liu Y, Rubinstein MM, Friedman CF, Rampal RK, Mandelker DL, Cadoo K, O’Cearbhaill RE. Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer. Gynecol Oncol Rep. 2021 Nov;38:100873. PubMed Central PMCID: PMC8651772.
5. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell. 2005 Dec 29;123(7):1213-26. PubMed PMID: 16377563.
Visit PubMed for a full listing of Dr. Al-Rawi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Duaa H. Al-Rawi discloses the following relationships and financial interests:
-
Amazon.com, Inc.
Equity -
Apple Inc
Equity -
Gilead Pharmaceutical
Equity
-
Google Inc
Equity -
Immuneering Corporation
Equity -
Microsoft Corporation
Equity
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.